Skip to content
Contact us for more information
We’re a team of driven individuals on a mission to radically improve the process of drug discovery.
The BioLoomics technology was developed over five years at CU Boulder, and funded by the DARPA Rapid Threat Assessment project. While addressing biological threats and building pipelines to create solutions, we realized this technology could be applied broadly to the pharmaceutical industry. That’s what we’re here to implement – Rapid drug assessments to improve efficacy, and enhance the probability that candidate drugs will pass Phase I clinical trials.
The People Behind BioLoomics
Dr. Douglas Chapnick
CEO & Founder
Director of Bioinformatics & Automation
Director of Operations
Toggle Sliding Bar Area
Revolutionizing drug discovery with genetic engineering, fluorescence microscopy, and machine learning.
Your Name (required)
Your Email (required)